Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 01:14 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED)
NCT00109538 · Merck Sharp & Dohme LLC · PHASE3 · terminated · last registry update 2015-05-01 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Merck Sharp & Dohme LLC |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against FNTA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2016-02-18Results posted on the registry: George Sledge, Lonafarnib (NCT00773474)
- 2016-02-18Also stopped (terminated): George Sledge, Lonafarnib (NCT00773474)
- 2015-11-10Results posted on the registry: National Cancer Institute (NCI), Tipifarnib (NCT00093470)
- 2015-08-27Also stopped (terminated): Merck Sharp & Dohme LLC, Lonafarnib (SARASAR) (NCT00050336)
- 2015-08-10Results posted on the registry: National Cancer Institute (NCI), fulvestrant + tipifarnib (NCT00082810)
- 2015-05-22Results posted on the registry: National Cancer Institute (NCI), tipifarnib + paclitaxel (NCT00470301)
- 2015-04-21Also stopped (terminated): Merck Sharp & Dohme LLC, Farnesyl Protein Transferase Inhibitor (NCT00073450)
- 2015-02-05Also stopped (terminated): Merck Sharp & Dohme LLC, Docetaxel plus lonafarnib (NCT00539968)
- 2014-05-26Results posted on the registry: National Cancer Institute (NCI), tipifarnib + etoposide (NCT00602771)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision